002107.SZ
沃华医药
SZSE · Healthcare · C 制造业 · CN
CNY 6.10
−2.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 784.9M | 817.0M | 763.8M | 909.5M | 1.0B |
| Cost of Revenue | 178.8M | 201.1M | 209.5M | 232.4M | 250.9M |
| Gross Profit | 606.2M | 615.8M | 554.3M | 677.1M | 763.9M |
| Operating Expenses | |||||
| R&D Expense | 32.7M | 36.4M | 40.7M | 45.4M | 50.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 63.2M | 66.1M | 74.7M | 77.3M | 67.3M |
| Selling & Marketing Expense | 366.1M | 407.3M | 388.7M | 491.8M | 521.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 473.9M | 520.2M | 512.1M | 624.6M | 651.5M |
| Cost and Expenses | 652.7M | 721.3M | 721.6M | 857.0M | 902.4M |
| Operating Income (EBIT) | 137.1M | 103.6M | 44.6M | 56.5M | 112.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 136.5M | 102.4M | 42.6M | 54.6M | 110.8M |
| Income Tax Expense | 17.8M | 13.6M | 8.9M | 8.0M | 20.9M |
| Bottom Line | |||||
| Net Income | 118.6M | 95.7M | 36.4M | 58.8M | 107.4M |
| Earnings from Cont. Ops | 118.6M | 88.9M | 34.3M | 46.6M | 89.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 118.6M | 95.7M | 36.4M | 58.8M | 107.4M |
| Per Share | |||||
| Basic EPS | CN¥0.20 | CN¥0.17 | CN¥0.06 | CN¥0.10 | CN¥0.19 |
| Diluted EPS | CN¥0.20 | CN¥0.17 | CN¥0.06 | CN¥0.10 | CN¥0.19 |
| Revenue Per Share | CN¥1.39 | CN¥1.45 | CN¥1.26 | CN¥1.55 | CN¥1.80 |
| Shares | |||||
| Basic Shares Outstanding | 563.1M | 563.0M | 606.7M | 587.7M | 565.2M |
| Diluted Shares Outstanding | 563.1M | 563.0M | 606.7M | 587.7M | 565.2M |
| Profitability Metrics | |||||
| EBITDA | — | 134.2M | 76.5M | 89.0M | 147.3M |
| D&A | — | 30.6M | 31.9M | 32.5M | 35.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026